Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro ... David Ricks, Eli Lilly’s chief ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

INDIANAPOLIS — Eli Lilly announced Wednesday the launch of higher doses of Zepbound — and that the company is lowering the price of certain doses. People taking Zepbound, or interested in starting, ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.